#biopharmaceuticals #Singapore #Automation #Haier Biomedical

Haier Biomedical Showcases Cutting-Edge Solutions at ISPE Singapore 2026

Haier Biomedical made a significant impact at the ISPE Singapore Conference & Exhibition 2026, held from August 20 to 21 at Suntec Singapore. As a leading event in pharmaceutical technology, the conference provided a platform for Haier Biomedical to reveal its latest advancements in automated and digital solutions designed to enhance workflows in pharmaceutical research, development, production, and quality control.

Highlights of Haier’s Presentation

During this prestigious event, Haier Biomedical presented a portfolio of innovative products, with a particular focus on their automated storage solution for maintaining samples at -80 °C. This technology debuted internationally at the conference, showcasing Haier's commitment to advancing biopharmaceutical infrastructure. Alongside this, the pilot freeze dryer was also introduced, underscoring their leadership in ultra-low temperature storage and the provision of integrated solutions across various biopharma categories.

The automated storage solution is engineered for pharma companies and research facilities that manage high-quality samples. It combines ultra-low temperature storage with smart sample management capabilities, ultimately increasing workflow efficiency and improving traceability. This product is perfectly tailored to meet the growing demands for automated and data-driven processes within the industry.

Bridging the Gap in Pharma Processes

The pilot freeze dryer featured in the presentation aims to help teams transition smoothly from laboratory research to subsequent production phases. By supporting pharmaceutical process development at a pilot scale, it addresses critical aspects of sample management, process development, and production, thus fulfilling complementary requirements that current workflows demand.

In a session dedicated to the theme of innovation, Haier Biomedical introduced its “Smart RFID ULT Storage Solution,” which weaves physical samples into the digital landscape. The embedded RFID tags facilitate unique identification of samples, while antennas within the storage units capture data without requiring direct line-of-sight scanning. This smart software associates each sample with its specific location and movement history, producing detailed structured entries of intake and output.

Customizable Solutions for Diverse Needs

The configurable nature of this system accommodates various sample formats, including vials, bags, tubes, and cryovials. Storage interfaces can be tailored with custom shelves, trays, and holders, fundamentally designed to enhance the user experience. The primary goal of interlinking sample identity, location, movement, and storage conditions is to minimize manual searches and inventory reconciliations, all while amplifying traceability throughout quality control, stock management, and supply chain logistics.

As the landscape of pharmaceutical operations increasingly trends toward automation and data-centricity, customers are seeking integrated workflows that connect samples, equipment, and data across research, production, and quality control domains. Haier's exhibit at ISPE reflected this broader vision, highlighting solutions extending from automation systems to ULT freezers, cooling centrifuges, and freeze-thaw systems designed to support pharmaceutical workflows from research development through to production, quality control, and cold storage.

A Shift Towards Comprehensive Solutions

Building upon its stronghold in ultra-low temperature storage, Haier Biomedical is expanding its global footprint in laboratory solutions, automation, and pharmaceutical applications. The shift from delivering single equipment to comprehensive multi-product portfolios and scenario-specific solutions marks a pivotal transformation. In the first half of 2026, Haier reported a 23% increase in revenue from pharmaceutical clients year-over-year, alongside a 19% rise in laboratory solutions revenue. Furthermore, AI-related business fields accounted for 18% of revenue, indicating a 3 percentage point increase compared to 2025.

By adapting its products and technologies to local regulations, infrastructures, and customer needs, Haier Biomedical remains at the forefront of enabling smarter, more interconnected, and scalable pharmaceutical research, development, and production systems. For more details, visit Haier Biomedical's website.